HK Stock Market Move | LEPU BIO-B(02157) is now up more than 4%, the injectable vedolizumab monoclonal antibody is planned to be included in priority review.

LEPU BIO-B (02157) is currently up more than 4%, at the time of writing, up 4.44% to 3.06 Hong Kong dollars, with a turnover of 8.1931 million Hong Kong dollars. In terms of news, on September 19, the website of the National Medical Products Administration's Drug Evaluation Center announced that Lepu Biologics' injection of Vebicotuximab monotherapy is proposed to be included in priority review. It is suitable for recurrent/metastatic nasopharyngeal carcinoma patients who have previously failed at least second-line systemic chemotherapy and PD-1/PD-L1 inhibitor therapy. It is reported that this drug is a targeted EGFR antibody-drug conjugate (ADC) developed by Lepu Biologics, with the research code MRG003. It is worth noting that Lepu Biologics' semi-annual report shows that MRG003 has already been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for nasopharyngeal carcinoma. Currently, Lepu Biologics has completed patient enrollment for the Phase 2b registration clinical trial of MRG003 for nasopharyngeal carcinoma. In addition, the product is also actively enrolling in a Phase 3 clinical registration study for head and neck squamous cell carcinoma.